Navigation Links
Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
Date:8/19/2007

NEW HAVEN, Conn., Aug. 15 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that the Company had paid interest due August 15, 2007 on its 7.75% Convertible Senior Notes due 2012 (the "Notes"). The aggregate principal amount of the Notes is $60 million.

The Company paid $2,260,416.67 in interest through the issuance of shares of its registered Common Stock. Approximately $2,259,888 was paid in 2,539,200 shares of Common Stock, based on today's closing bid price of $0.89, which is approximately equal to 42.32 of shares of Common Stock per each $1,000 principal amount of Notes. Cash interest was paid in lieu of fractional shares.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. A Phase II trial of Cloretazine(R) (VNP40101M) in small cell lung cancer is also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is also evaluating VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company also is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's Internet web site at '/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Anthropology professors blog raises public interest
4. Interest drives investment of instructional technology
5. High interest forces delay in food safety symposium
6. A Vote Against Free Trade is a Vote Against Wisconsins Long-Term Interests
7. SecurePipe appoints two senior execs
8. Third Wave announces two senior management appointments
9. Senior Wisconsin stem-cell researcher leaves for Connecticut
10. Sonic Foundry names new senior vice president
11. Eppendorf Electroporation Application Notes Your participation is highly welcome !!!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014 OTC Markets ... Inc., a biotechnology company, on its approval to ... traded on OTCQX®, the best marketplace for established ... Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... successful execution of its growth strategy and achievement ...
(Date:8/21/2014)... 21, 2014 Pursuit Solutions ( ... technology and services for Life Sciences sales and ... Use of New Commercial Sales Models” by Peter ... , The article examines some innovative models used ... being tested in the pharmaceutical market. Robinson grades ...
(Date:8/21/2014)... SoundConnect , a unified communication ... of the nation’s Fastest Growing Private Companies by ... consecutive year. Inc. magazine today ranked SoundConnect NO. ... exclusive ranking of the nation's fastest-growing private companies. ... the most important segment of the economy—America’s independent ...
(Date:8/20/2014)... of patented university inventions licensed to biotechnology firms ... commercialization. To open these roadblocks, the researchers suggest ... the discovery stage could lead to faster commercialization ... derived from discoveries made in university laboratories and ... during clinical trials, which have a high failure ...
Breaking Biology Technology:OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... DUBLIN, Calif., Feb. 28 Microchip Biotechnologies, ... develop a front-end,microfluidic based sample preparation system ... The goal of the project is to ... MBI,s,Microscale-On-chip-Valves (MOV(TM)) for Superscalar Pyrosequencing. "Using,MBI,s MOV ...
... US Oncology Holdings, Inc. ("Holdings",or the "Company"), the ... the nation,s largest cancer services companies, reported revenue of,$771.6 ... million,net loss of $14.8 million and operating cash flow ... For the year ended December 31, 2007, the,Company reported ...
... N.J., Feb. 28 Pharmacopeia,(Nasdaq: PCOP ), ... novel,small molecule therapeutics, today announced advancements for two ... President, Clinical and,Regulatory Affairs, has been promoted to ... role of S. David Kimball, Ph.D., Senior,Vice President, ...
Cached Biology Technology:Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms 2US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 2US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 4US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 5US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 6US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 7US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 8US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 9US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 10US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 11US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 12US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 13US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 14US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 15US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 16US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 17US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 18US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 19US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 20US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 21US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 22US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 23US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 24US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 25US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 26Pharmacopeia Announces Management Team Changes 2Pharmacopeia Announces Management Team Changes 3Pharmacopeia Announces Management Team Changes 4Pharmacopeia Announces Management Team Changes 5
(Date:8/20/2014)... HOUSTON, Aug. 20, 2014 George E. Fox, a John ... University of Houston (UH), was named a fellow in the ... (ISSOL). , Fox is one of four members ... Spain chosen as fellows in 2014. Fellows are elected ... With more than 500 members from more than 20 countries, ...
(Date:8/20/2014)... 20, 2014 /CNW/ -  Issue Serious ... quickly become life threatening for some children.    ... million Canadians have food allergies and this number may be ... children are estimated to have food allergies.  ... irritations and hives to breathing difficulties and loss of consciousness. ...
(Date:8/20/2014)... Bay Area Lyme Foundation, which aims to make Lyme ... new research published in an upcoming issue of the ... . The findings show that ticks that carry ... year, making the threat of Lyme disease year-round. The ... Public Health (CDPH) Vector-borne Disease Section and University of ...
Breaking Biology News(10 mins):UH professor named fellow by International Astrobiology Society 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3
... N.Y. With fewer than a dozen flowering plants out ... intake, people need to tap unused plants to feed the ... Susan McCouch in the Comment feature of the July 4 ... population growth and rising incomes around the world, researchers estimate ...
... TORONTO - A team of Toronto-based researchers may be one ... cells for use in research and therapy. Induced pluripotent ... research because they can flexibly develop into many different types ... proteins that control their generation are largely unknown. But ...
... Gondwana Research , has revealed the past position ... how they formed the supercontinent Gondwana 165 million years ... National University and Geoscience Australia, have helped clear up ... they should be positioned when drawing up a picture ...
Cached Biology News:To feed the future, we must mine the wealth of the world's seed banks today 2Toronto team ID proteins key in stem cell production 2
... protein into cells permits studies of protein-protein ... pathways, and transcription factor-mediated gene regulation. The ... of a specific protein in a mammalian ... into the cell. ProteoJuice Protein Transfection Reagent ...
... is an automated instrument with a thin ... real-time using light or fluorescence microscopy. Biaxial ... and fibroblast cells can be simulated by ... and Y axis of our strain chamber. ...
... Solutions has now entered the next frontier ... partnering up with Cellomics, Inc. The drug ... of Beckman Coulter‘s automated solutions systems and ... information at the sub-cellular level. The integration ...
... biologic production demands on cell and tissue ... cell populations. Therefore, both cell concentration and ... accurately and precisely. The new Vi-CELLTM Cell ... effective means to perform the trypan blue ...
Biology Products: